Literature DB >> 15781834

Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening.

C C P Verstappen1, S Koeppen, J J Heimans, P C Huijgens, M E Scheulen, D Strumberg, B Kiburg, T J Postma.   

Abstract

This study describes the natural course of vincristine-induced peripheral neuropathy in patients with lymphoma (n = 114) receiving vincristine in two different dose intensities. Neuropathic changes were observed in both dose intensity groups, but the higher dose intensity group reported significantly more symptoms during therapy, whereas neurologic signs were significantly more prominent after a cumulative dose of 12 mg vincristine. Furthermore, off-therapy worsening of symptoms (24%) and signs (30%) occurred unexpectedly.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15781834     DOI： 10.1212/01.WNL.0000154642.45474.28

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  40 in total

1.  Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy.

Authors:  Laurence Meyer; Christine Patte-Mensah; Omar Taleb; Ayikoe Guy Mensah-Nyagan
Journal:  Cell Mol Life Sci       Date:  2010-04-30       Impact factor: 9.261

2.  Chemotherapy agents: a primer for the interventional radiologist.

Authors:  Frank Mihlon; Charles E Ray; Wells Messersmith
Journal:  Semin Intervent Radiol       Date:  2010-12       Impact factor: 1.513

Review 3.  Emerging trends in understanding chemotherapy-induced peripheral neuropathy.

Authors:  Jérémy Ferrier; Vanessa Pereira; Jérome Busserolles; Nicolas Authier; David Balayssac
Journal:  Curr Pain Headache Rep       Date:  2013-10

4.  Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype.

Authors:  Timothy N Phoenix; Deanna M Patmore; Scott Boop; Nidal Boulos; Megan O Jacus; Yogesh T Patel; Martine F Roussel; David Finkelstein; Liliana Goumnerova; Sebastien Perreault; Elizabeth Wadhwa; Yoon-Jae Cho; Clinton F Stewart; Richard J Gilbertson
Journal:  Cancer Cell       Date:  2016-03-31       Impact factor: 31.743

Review 5.  Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies.

Authors:  Gerardo Gutiérrez-Gutiérrez; María Sereno; Ambrosio Miralles; Enrique Casado-Sáenz; Eduardo Gutiérrez-Rivas
Journal:  Clin Transl Oncol       Date:  2010-02       Impact factor: 3.405

Review 6.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

7.  Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia.

Authors:  Ellen M Lavoie Smith; Lang Li; ChienWei Chiang; Karin Thomas; Raymond J Hutchinson; Elizabeth M Wells; Richard H Ho; Jodi Skiles; Arindom Chakraborty; Celia M Bridges; Jamie Renbarger
Journal:  J Peripher Nerv Syst       Date:  2015-03       Impact factor: 3.494

Review 8.  Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith
Journal:  Semin Oncol Nurs       Date:  2019-04-30       Impact factor: 2.315

Review 9.  Cancer pharmacogenomics in children: research initiatives and progress to date.

Authors:  Shahrad Rod Rassekh; Colin J D Ross; Bruce C Carleton; Michael R Hayden
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

10.  Anti-allodynic effect of theoesberiven F in a vincristine-induced neuropathy model.

Authors:  Seunguk Bang; Yee Suk Kim; Sang Rok Jeong
Journal:  Exp Ther Med       Date:  2016-05-26       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.